Aberdeen Group Trims Stake in Cytokinetics

Institutional investor reduces position in biopharmaceutical company by nearly 50%

Apr. 5, 2026 at 7:09am

Got story updates? Submit your updates here. ›

Aberdeen Group plc, a major institutional investor, has reduced its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 47.9% during the fourth quarter, according to a recent SEC filing. The fund now owns 483,061 shares of the biopharmaceutical company's stock, down from over 900,000 shares previously.

Why it matters

Cytokinetics is a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function. As an institutional investor, Aberdeen Group's trading activity can signal broader market sentiment and investor confidence in the company's pipeline and future prospects.

The details

According to the 13F filing, Aberdeen Group sold 444,771 shares of Cytokinetics during the fourth quarter. The fund now owns approximately 0.40% of the company's outstanding shares, down from 0.77% previously. Cytokinetics is developing several drug candidates, including omecamtiv mecarbil for the treatment of heart failure.

  • The 13F filing covers the fourth quarter of 2025.

The players

Aberdeen Group plc

A major institutional investor that has reduced its stake in Cytokinetics by nearly 50%.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

Aberdeen Group's reduced position in Cytokinetics could signal broader market uncertainty about the company's drug pipeline or future growth prospects, though the stock remains a 'Moderate Buy' among Wall Street analysts. Investors will be watching for any further changes in institutional ownership and updates on Cytokinetics' clinical development programs.